Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (178) clinical trials

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 ...

Phase

5.43 miles

Learn More »

Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to ...

Phase

5.43 miles

Learn More »

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

The study will be conducted in two segments. The first segment of the study, designated Phase 1a, will be a dose escalation design in order to assess the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of ascending doses of AZD4635 as monotherapy, in combination with durvalumab or durvalumab plus ...

Phase

5.43 miles

Learn More »

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Phase

5.43 miles

Learn More »

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

This is a first-in-human, two-part, open-label, safety, pharmacokinetic, and efficacy study of oral CK-101 administered daily in ascending doses in patients with advanced solid tumor cancer, followed by a Phase 2 portion at the recommended Phase 2 dose (RP2D) in previously treated non-small cell lung cancer (NSCLC) patients who have ...

Phase

5.43 miles

Learn More »

Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Approximately 30 subjects across approximately 5 United States (US) sites will be enrolled in the Phase 1 portion of the study and approximately 69-84 subjects across approximately 15 US sites will be enrolled in the Phase 2A portion of the study. The Phase 1 portion of the study will follow ...

Phase

5.43 miles

Learn More »

Confirmatory Clinical Study of Oxiplex

This is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded clinical study to assess the safety and effectiveness for the reduction of pain and symptoms following lumbar surgery.

Phase N/A

5.43 miles

Learn More »

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

This study tests the new medicine BI 754111 alone or in combination with BI 754091 in patients with advanced cancer. The study tests different doses to find the best dose for continuous treatment

Phase

5.43 miles

Learn More »

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for further development of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, ...

Phase

5.43 miles

Learn More »

AZD5153 in Patients With Relapsed or Refractory Solid Tumors Including Lymphomas

The trial will be conducted in two parts, dose escalation and dose expansion. AZD5153 will be investigated as a monotherapy and in combination with olaparib. AZD5153 monotherapy (dose escalation): This part of the study will enroll patients with advanced solid malignancies, including lymphoma, and test safety and tolerability of AZD5153 ...

Phase

5.43 miles

Learn More »